Jessica Hou 2023


1315 Capital


Jessica joined 1315 Capital as Partner in 2022, bringing significant healthcare investing experience in growth stage companies. She spent 9 years at Montreux Growth Partners, a healthcare growth capital firm based in San Francisco, most recently as Managing Director. Previously, she was a healthcare investor at Quaker Partners. She has executed and managed investments in healthcare technology and services, specialty pharmaceutical, biopharmaceutical, medical device, diagnostics, and consumer healthcare companies.

Jessica currently serves on the board of NutriSense and Colorescience (a Montreux and 1315 Capital co-investment). Previously, she served on the board or as a board observer at FinPay, Crown Laboratories, TigerConnect (Vista Equity Partners), SI-BONE (NASDAQ: SIBN), KFx Medical (exited), and Tobira Therapeutics (NASDAQ: TBRA, acquired by Allergan).

Jessica started her career in the healthcare and life sciences practice at Navigant Consulting. She also worked in marketing at Abbott on the global launch of its bioresorbable stent. She has contributed to policy and research initiatives with the Medical Innovation and Competitiveness (MedIC) Coalition and National Venture Capital Association (NVCA).

Jessica received a BA with distinction in Human Biology and English from Stanford University and an MBA from Stanford Graduate School of Business.